Compositions for treating metastatic and invasive cancers

Antibodies targeting the polymeric immunoglobulin receptor (plgR) with defined CDRs are used to disrupt cancer nests, addressing the limitations of current treatments for invasive and metastatic cancers by specifically targeting their microarchitecture.

WO2026236428A2PCT designated stage Publication Date: 2026-11-12PATHCISION MEDICINE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027009
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for locally invasive and metastatic cancer do not effectively target the formation of cancer nests with closed apical lumens, a key mechanism in cancer pathogenesis and metastasis.

Method used

Compositions comprising antibodies or binding fragments that specifically bind to the polymeric immunoglobulin receptor (plgR) with defined heavy and light chain complementarity determining regions (CDRs) are developed to target and disrupt cancer nests.

Benefits of technology

These compositions effectively target and disrupt cancer nests, potentially enhancing treatment efficacy for locally invasive and metastatic cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027009_12112026_PF_FP_ABST
    Figure US2026027009_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present application discloses compositions comprising antibodies or binding fragments thereof which specifically bind to a polymeric immunoglobulin receptor (pIgR). Also described are methods for treating cancers comprising administering to a subject any of the compositions comprising the antibodies or binding fragments thereof disclosed herein. In some embodiments, the cancer is metastatic or locally invasive.
Need to check novelty before this filing date? Find Prior Art

Description

WSGR Docket No. 67237-702.601COMPOSITIONS FOR TREATING METASTATIC AND INVASIVE CANCERS CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Patent Application No.63 / 803,223, filed on May 09, 2025, which is incorporated herein by reference in its entirety.BACKGROUND

[0002] Cancer is a leading cause of death worldwide. The ability to invade and metastasize is a key mechanism of cancer pathogenesis and results in increased cancer growth. Local invasion and distal metastasis are the strongest factors contributing to deaths caused by cancer. Thus, there is a need for new treatments for locally invasive and metastatic cancer. A shared common feature between local invasion and metastasis is the formation of cancer nests having the microarchitecture of closed apical lumen, which the compositions disclosed herein leverage for treatment.SUMMARY OF THE DISCLOSURE

[0003] Provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4, 11, 18, 25, 32, 39, 43, 49, 56, 61, 68, 75, 88, 95, 102, 109, 116, 123, 130, 137, 144, 151, 158, 165, 172, 179, 186, 193, 200, 207, 214, 221, 228, 235, 242, 249, 256, 263, 270, 277, 284, 291, 298, 305, 312, 319, 326, 333, 340, 347, 354, 361, 368, 375, or 382. In some embodiments, the heavy chain comprises a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 48, 55, 67, 74, 87, 94, 101, 108, 115, 122, 129, 136, 143, 150, 157, 164, 171, 178, 185, 192, 199, 206, 213, 220, 227, 234, 241, 248, 255, 262, 269, 276, 283, 290, 297, 304, 311, 318, 325, 332, 339, 346, 353, 360, 367, 374, or 381. In some embodiments, the heavy chain further comprises a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 47, 54, 66, 73, 86, 93, 100, 107, 114, 121, 128, 135, 142, 149, 156, 163, 170, 177, 184, 191, 198, 205, 212, 219, 226, 233, 240, 247, 254, 261, 268, 275, 282, 289, 296, 303, 310, 317, 324, 331, 338, 345, 352, 359, 366, 373, or 380. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 7, 14, 21, 28, 35, , 45, 52, 59, 64, 71, 78, 91, 98, 105, 112, 119, 126, 133, 140, 147, 154, 161, 168, 175, 182,WSGR Docket No. 67237-702.601189, 196, 203, 210, 217, 224, 231, 238, 245, 252, 259, 266, 273, 280, 287, 294, 301, 308, 315, 322, 329, 336, 343, 350, 357, 364, 371, 378, or 385. In some embodiments, the light chain comprises a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from WAS, GTS, YAS, NAK, RVN, YTS, or TVS. In some embodiments, the light chain comprises a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6, 13, 20, 27, 34, 41, 51, 58, 63, 70, 77, 90, 97, 104, 111, 118, 125, 132, 139, 146, 153, 160, 167, 174, 181, 188, 195, 202, 209, 216, 223, 230, 237, 244, 251, 258, 265, 272, 279, 286, 293, 300, 307, 314, 321, 328, 335, 342, 349, 356, 363, 370, 377, or 384. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to any one of SEQ ID NOs: 1, 8, 15, 22, 29, 36, 42, 46, 53, 60, 65, 72, 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, 162, 169, 176, 183, 190, 197, 204, 211, 218, 225, 232, 239, 246, 253, 260, 267, 274, 281, 288, 295, 302, 309, 316, 323, 330, 337, 344, 351, 358, 365, 372, or 379. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to any one of SEQ ID NOs: 5, 12, 19, 26, 33, 40, 44, 50, 57, 62, 69, 76, 89, 96, 103, 110, 117, 124, 131, 138, 145, 152, 159, 166, 173, 180, 187, 194, 201, 208, 215, 222, 229, 236, 243, 250, 257, 264, 271, 278, 285, 292, 299, 306, 313, 320, 327, 334, 341, 348, 355, 362, 369, 376 or 383.

[0004] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 4; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 7; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 6.

[0005] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 11; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 10; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 9; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 14; (ii) a LCDR2 comprising a sequence of GTS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 13.WSGR Docket No. 67237-702.601

[0006] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 18; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 17; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 16; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 21; (ii) a LCDR2 comprising a sequence of YAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 20.

[0007] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 25; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 24; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 23; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 28; (ii) a LCDR2 comprising a sequence of NAK; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 27.

[0008] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 32; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 31; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 30; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 35; (ii) a LCDR2 comprising a sequence of RVN; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 34.

[0009] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 39; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 38; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 37; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 14; (ii) a LCDR2 comprising a sequence of GTS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 41.

[0010] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3WSGR Docket No. 67237-702.601comprising a sequence set forth in SEQ ID NO: 43; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 45; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 6.

[0011] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 49; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 48; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 47; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 52; (ii) a LCDR2 comprising a sequence of YAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 51.

[0012] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 56; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 55; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 54; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 59; (ii) a LCDR2 comprising a sequence of YTS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 58.

[0013] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 61; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 64; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 63.

[0014] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 68; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 67; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 66; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 71;WSGR Docket No. 67237-702.601(ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 70.

[0015] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 75; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 74; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 73; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 78; (ii) a LCDR2 comprising a sequence of TVS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 77.

[0016] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 88; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 87; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 86; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 91; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 90.

[0017] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 95; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 94; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 93; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 98; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 97.

[0018] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 102; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 101; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 100; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 105; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 104.WSGR Docket No. 67237-702.601

[0019] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 109; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 108; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 107; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 112; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 111.

[0020] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 116; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 115; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 114; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 119; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 118.

[0021] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 123; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 122; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 121; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 126; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 125.

[0022] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 130; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 129; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 128; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 133; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 132.

[0023] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3WSGR Docket No. 67237-702.601comprising a sequence set forth in SEQ ID NO: 137; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 136; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 135; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 140; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 139.

[0024] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 144; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 143; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 142; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 147; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 146.

[0025] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 151; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 150; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 149; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 154; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 153.

[0026] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 158; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 157; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 156; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 161; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 160.

[0027] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 165; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 164; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 163; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO:WSGR Docket No. 67237-702.601168; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 167.

[0028] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 172; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 171; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 170; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 175; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 174.

[0029] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 179; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 178; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 177; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 182; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 181.

[0030] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 186; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 185; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 184; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 189; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 188.

[0031] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 193; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 192; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 191; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 196; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 195.WSGR Docket No. 67237-702.601

[0032] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 200; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 199; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 198; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 203; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 202.

[0033] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 207; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 206; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 205; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 210; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 209.

[0034] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 214; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 213; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 212; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 217; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 216.

[0035] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 221; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 220; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 219; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 224; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 223.

[0036] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3WSGR Docket No. 67237-702.601comprising a sequence set forth in SEQ ID NO: 228; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 227; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 226; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 231; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 230.

[0037] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 235; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 234; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 233; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 238; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 237.

[0038] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 242; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 241; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 240; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 245; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 244.

[0039] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 249; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 248; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 247; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 252; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 251.

[0040] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 256; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 255; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 254; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO:WSGR Docket No. 67237-702.601259; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 258.

[0041] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 263; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 262; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 261; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 266; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 265.

[0042] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 270; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 269; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 268; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 273; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 272.

[0043] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 277; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 276; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 275; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 280; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 279.

[0044] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 284; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 283; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 282; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 287; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 286.WSGR Docket No. 67237-702.601

[0045] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 291; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 290; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 289; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 294; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 293.

[0046] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 298; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 297; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 296; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 301; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 300.

[0047] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 305; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 304; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 303; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 308; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 307.

[0048] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 312; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 311; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 310; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 315; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 314.

[0049] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3WSGR Docket No. 67237-702.601comprising a sequence set forth in SEQ ID NO: 319; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 318; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 317; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 322; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 321.

[0050] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 326; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 325; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 324; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 329; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 328.

[0051] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 333; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 332; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 331; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 336; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 335.

[0052] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 340; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 339; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 338; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 343; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 342.

[0053] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 347; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 346; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 345; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO:WSGR Docket No. 67237-702.601350; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 349.

[0054] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 354; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 353; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 352; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 357; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 356.

[0055] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 361; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 360; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 359; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 364; (ii) a LCDR2 comprising a sequence of WAS; and (iii) LCDR1 comprising a sequence set forth in SEQ ID NO: 363.

[0056] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 368; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 367; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 366; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 371; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 370.

[0057] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 375; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 374; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 373; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 378; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 377.WSGR Docket No. 67237-702.601

[0058] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 382; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 381; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 380; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 385; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 384.

[0059] In some embodiments, the antibody or the binding fragment thereof binds to plgR with an affinity of at least InM, at least 0. InM, at least O.OlnM, at least IpM, at least lOOnM, or at least 50nM. In some embodiments, the composition is capable of inducing transcytosis via the activity of plgR. In some embodiments, when contacted to plgR, the antibody or the binding fragment thereof exhibits an increase of at least 1%, at least 5%, at least 10%, at least 20%, or at least 30% in transcytosis compared to an antibody that is not specific for plgR. In some embodiments, the antibody or the binding fragment thereof, when contacted to an endothelial barrier expressing plgR, exhibits an increase of at least 1%, at least 5%, at least 10%, at least 20%, or at least 30% in transcytosis into the lumen compared to an antibody that is not specific for plgR. In some embodiments, the antibody or the binding fragment thereof, when contacted to an epithelial barrier expressing plgR, exhibits an increase of at least 1%, at least 5%, at least 10%, at least 20%, or at least 30%in transcytosis into the lumen compared to an antibody that is not specific for plgR. In some embodiments, the antibody or the binding fragment thereof is a scFv. In some embodiments, the antibody or the binding fragment thereof is a sdAb, a Fab, or a VHH. In some embodiments, the antibody or the binding fragment thereof is an IgG molecule. In some embodiments, the IgG molecule is IgGl, IgG2, IgG3, or IgG4. In some embodiments, the IgG2 molecule is IgG2a, IgG2b, or IgG2c. In some embodiments, the IgG molecule is a mouse IgG (mlgG) or human IgG molecule (hlgG). In some embodiments, the IgG molecule is an IgGl molecule. In some embodiments, the IgGl molecule is a human IgGl (hlgGl) molecule. In some embodiments, the hlgGl comprises one or more mutations. In some embodiments, the one or more mutations are selected from the group consisting of L234A, L235A, P329G in the hlgGl heavy chain, and any combination thereof. In some embodiments, the one or more mutations result in a reduction in Fc activity of the IgG molecule compared to an otherwise identical IgG molecule which does not comprise the one or more mutations. In some embodiments, the antibody or binding fragment thereof comprises a constant region having an amino acid sequence with at least 80% sequence identity to a sequence set forth in SEQ ID NO: 80 or 81.WSGR Docket No. 67237-702.601

[0060] Also provided herein is a nucleic acid encoding the antibody or the binding fragment thereof of any one of the foregoing embodiments.

[0061] Also provided herein is a vector comprising the nucleic acid of any one of the foregoing embodiments.

[0062] Also provided herein is a cell comprising (a) the antibody or the binding fragment thereof of any one of the foregoing embodiments; (b) the nucleic acid of any one of the foregoing embodiments; or (c) the vector of any one of the foregoing embodiments.

[0063] Also provided herein is a composition comprising (a) the antibody or the binding fragment thereof of any one of the foregoing embodiments; (b) the nucleic acid of any one of the foregoing embodiments; (c) the vector of any one of the foregoing embodiments; or (d) the cell of any one of the foregoing embodiments.

[0064] Also provided herein is a pharmaceutical composition comprising (a) the antibody or the binding fragment thereof of any one of the foregoing embodiments, the nucleic acid of any one of the foregoing embodiments, the vector of any one of the foregoing embodiments, the cell of any one of the foregoing embodiments, or the composition of any one of the foregoing embodiments and (b) a pharmaceutically acceptable excipient.

[0065] Also provided herein is a method of treating a plgR-expressing cancer in a subject in need thereof, the method comprising administering the antibody or the binding fragment thereof of any one of the foregoing embodiments, the nucleic acid of any one of the foregoing embodiments, the vector of any one of the foregoing embodiments, the cell of any one of the foregoing embodiments, the composition of any one of the foregoing embodiments, or the pharmaceutical composition of any one of the foregoing embodiments.

[0066] Also provided herein is a method of treating a metastasis or a local invasion of a plgR-expressing cancer in a subject in need thereof, the method comprising administering the antibody or the binding fragment thereof of any one of the foregoing embodiments, the nucleic acid of any one of the foregoing embodiments, the vector of any one of the foregoing embodiments, the cell of any one of the foregoing embodiments, the composition of any one of the foregoing embodiments, or the pharmaceutical composition of any one of the foregoing embodiments. In some embodiments, the plgR-expressing cancer is selected from the group consisting of a colorectal cancer, a pancreatic cancer, a gastric cancer, an esophageal cancer, a kidney cancer, an endometrial cancer, a cervical cancer, a breast cancer, a prostate cancer, a urinary bladder cancer, a cancer of the head and neck, a liver cancer, a gallbladder cancer, an ovarian cancer, and a non-small cell lung cancer.WSGR Docket No. 67237-702.601INCORPORATION BY REFERENCE

[0067] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such contradictory material.BRIEF DESCRIPTION OF THE DRAWINGS

[0068] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

[0069] FIG. 1 depicts an exemplary workflow describing a process to identify and screen anti-plgR antibodies.

[0070] FIG.2 depicts biolayer interferometry (BLI) data obtained using an anti-pIgR binder in an scFv format.DETAILED DESCRIPTIONPolymeric Immunoglobulin Receptor (plgR)

[0071] The polymeric immunoglobulin receptor (plgR) is a highly conserved transmembrane protein that is commonly expressed in mucosal epithelial cells, e.g., in the gastrointestinal tract where these cells form a barrier between the intestinal lumen and the basal stroma of the lamina propria. The primary function of plgR is to traffic polymeric immunoglobulin (pig) produced by antibody-secreting cells in lamina propria to the lumen, where they can mediate anti-microbial functions and regulate the microbiome. In order to accomplish trafficking, the secreted immunoglobulins (e.g., dimeric IgA or pentameric IgM) bind to plgR, which triggers a transcytosis mechanism that begins to traffic the immunoglobulin / receptor complex through the epithelial cell. A proteolytic cleavage step then occurs which frees the pig along with a secretory component derived from the plgR, together called the secretory Ig, into the lumenal space. In some embodiments, the plgR (Uniprot ID: P01833) comprises a sequence of MLLFVLTCLLAVFPAISTKSPIFGPEEVNSVEGNSVSITCYYPPTSVNRHTRKYWCRQGA RGGCITLISSEGYVSSKYAGRANLTNFPENGTFVVNIAQLSQDDSGRYKCGLGINSRGLS FDVSLEVSQGPGLLNDTKVYTVDLGRTVTINCPFKTENAQKRKSLYKQIGLYPVLVIDSSWSGR Docket No. 67237-702.601 GYVNPNYTGRIRLDIQGTGQLLFSVVINQLRLSDAGQYLCQAGDDSNSNKKNADLQVL KPEPELVYEDLRGSVTFHCALGPEVANVAKFLCRQSSGENCDVVVNTLGKRAPAFEGRI LLNPQDKDGSFSVVITGLRKEDAGRYLCGAHSDGQLQEGSPIQAWQLFVNEESTIPRSPT VVKGVAGGSVAVLCPYNRKESKSIKYWCLWEGAQNGRCPLLVDSEGWVKAQYEGRL SLLEEPGNGTFTVILNQLTSRDAGFYWCLTNGDTLWRTTVEIKIIEGEPNLKVPGNVTAV LGETLKVPCHFPCKFSSYEKYWCKWNNTGCQALPSQDEGPSKAFVNCDENSRLVSLTL NLVTRADEGWYWCGVKQGHFYGETAAVYVAVEERKAAGSRDVSLAKADAAPDEKV LDSGFREIENKAIQDPRLFAEEKAVADTRDQADGSRASVDSGSSEEQGGSSRALVSTLVP LGLVLAVGAVAVGVARARHRKNVDRVSIRSYRTDISMSDFENSREFGANDNMGASSIT QETSLGGKEEFVATTESTTETKEPKKAKRSSKEEAEMAYKDFLLQSSTVAAEAQDGPQEA (SEQ ID NO: 79). In some embodiments, the plgR comprises a sequence having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 79.Anti-pIgR Binders

[0072] Provided herein are anti-pIgR binders. In some embodiments, the anti-pIgR binder is an plgR agonist. In some embodiments, the anti-pIgR binder is a plgR activator. In some embodiments, the plgR binder is configured to transcytose via the activity of plgR. In some embodiments, the plgR binder is configured to transcytose to the interior space of the closed apical lumen microarchitecture of a cancer when contacted to plgR. In some embodiments, the anti-pIgR binder is an antibody or a binding fragment thereof. In some embodiments, the anti-plgR binder is a single-domain antibody (sdAb, - for example, as a VHH).

[0073] Provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4, 11, 18, 25, 32, 39, 43, 49, 56, 61, 68, 75, 88, 95, 102, 109, 116, 123, 130, 137, 144, 151, 158, 165, 172, 179, 186, 193, 200, 207, 214, 221, 228, 235, 242, 249, 256, 263, 270, 277, 284, 291, 298, 305, 312, 319, 326, 333, 340, 347, 354, 361, 368, 375, or 382. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 25. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 39. In some embodiments, the HCDR3 comprisesWSGR Docket No. 67237-702.601an amino acid sequence set forth in SEQ ID NO: 43. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 49. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 61. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 75. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 95. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 102. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 109. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 116. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 123. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 137. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 151. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 158. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 172. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 179. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 186. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 193. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 200. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 207. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 214. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 221. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 228. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 235. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 242. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 249. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 256. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 263. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ IDWSGR Docket No. 67237-702.601NO: 270. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 277. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 284. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 291. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 298. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 305. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 312. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 319. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 326. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 333. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 340. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 347. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 354. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 361. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 368. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 375. In some embodiments, the HCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 382.

[0074] In some embodiments, the heavy chain comprises a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in any one of SEQ IDNOs: 3, 10, 17, 24, 31, 38, 48, 55, 67, 74, 87, 94, 101, 108, 115, 122, 129, 136, 143, 150, 157, 164, 171, 178, 185, 192, 199, 206, 213, 220, 227, 234, 241, 248, 255, 262, 269, 276, 283, 290, 297, 304, 311, 318, 325, 332, 339, 346, 353, 360, 367, 374, or 381. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 24. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 38. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 48. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 55. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 67. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 74. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 87. In some embodiments, the HCDR2 comprises an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 94. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 101. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 108. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 115. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 122. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 129. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 136. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 143. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 150. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 157. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 164. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 171. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 178. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 185. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 192. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 199. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 206. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 213. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 220. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 227. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 234. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 241. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 248. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 255. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 262. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 269. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 276. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 283. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 290. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 297. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 304. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 311. In some embodiments, the HCDR2 comprises an amino acid sequence set forth inWSGR Docket No. 67237-702.601SEQ ID NO: 318. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 325. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 332. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 339. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 346. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 353. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 360. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 367. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 374. In some embodiments, the HCDR2 comprises an amino acid sequence set forth in SEQ ID NO: 381.

[0075] In some embodiments, the heavy chain further comprises a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in any one of SEQ IDNOs: 2, 9, 16, 23, 30, 37, 47, 54, 66, 73, 86, 93, 100, 107, 114, 121, 128, 135, 142, 149, 156, 163, 170, 177, 184, 191, 198, 205, 212, 219, 226, 233, 240, 247, 254, 261, 268, 275, 282, 289, 296, 303, 310, 317, 324, 331, 338, 345, 352, 359, 366, 373, or 380. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 23. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 30. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 47. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 86. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 93. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 114. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 121. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 128. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 135. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO:WSGR Docket No. 67237-702.601142. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 149. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 156. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 163. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 170. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 184. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 191. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 198. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 205. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 212. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 226. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 233. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 240. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 247. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 254. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 261. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 268. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 275. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 282. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 289. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 296. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 303. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 310. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 317. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 324. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 331. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 338. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 345. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 352. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 359. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 366. In some embodiments, theWSGR Docket No. 67237-702.601HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 373. In some embodiments, the HCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 380.

[0076] In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 7, 14, 21, 28, 35, 45, 52, 59, 64, 71, 78, 91, 98, 105, 112, 119, 126, 133, 140, 147, 154, 161, 168, 175, 182, 189, 196, 203, 210, 217, 224, 231, 238, 245, 252, 259, 266, 273, 280, 287, 294, 301, 308, 315, 322, 329, 336, 343, 350, 357, 364, 371, 378, or 385. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 28. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 35. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 45. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 71. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 78. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 91. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 98. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 105. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 112. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 119. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 126. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 133. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 140. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 147. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 154. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 161. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 168. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 175. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 182. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ IDWSGR Docket No. 67237-702.601NO: 189. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 196. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 203. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 210. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 217. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 224. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 231. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 238. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 245. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 252. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 259. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 266. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 273. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 280. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 287. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 294. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 301. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 308. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 315. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 322. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 329. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 336. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 343. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 350. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 357. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 364. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 371. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 378. In some embodiments, the LCDR3 comprises an amino acid sequence set forth in SEQ ID NO: 385.

[0077] In some embodiments, the light chain comprises a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from WAS, GTS, YAS, NAK, RVN, YTS, or TVS. In some embodiments, the LCDR2 comprises an amino acid sequence of WAS. In some embodiments, the LCDR2 comprises an amino acid sequence ofWSGR Docket No. 67237-702.601GTS. In some embodiments, the LCDR2 comprises an amino acid sequence of YAS. In some embodiments, the LCDR2 comprises an amino acid sequence of NAK. In some embodiments, the LCDR2 comprises an amino acid sequence of RVN. In some embodiments, the LCDR2 comprises an amino acid sequence of YTS. In some embodiments, the LCDR2 comprises an amino acid sequence of TVS.

[0078] In some embodiments, the light chain comprises a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ IDNOs: 6, 13, 20, 27, 34, 41, 51, 58, 63, 70, 77, 90, 97, 104, 111, 118, 125, 132, 139, 146, 153, 160, 167, 174, 181, 188, 195, 202, 209, 216, 223, 230, 237, 244, 251, 258, 265, 272, 279, 286, 293, 300, 307, 314, 321, 328, 335, 342, 349, 356, 363, 370, 377, or 384. In some embodiments, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 6. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 20. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 34. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 51. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 63. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 70. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 77. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 90. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 97. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 104. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 111. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 118. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 125. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 132. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 139. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 153. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 167. In some embodiments, the LCDR1 comprises an amino acid sequence setWSGR Docket No. 67237-702.601forth in SEQ ID NO: 174. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 181. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 188. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 195. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 202. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 209. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 216. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 223. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 230. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 237. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 244. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 251. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 258. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 265. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 272. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 279. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 286. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 300. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 307. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 314. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 321. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 328. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 335. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 342. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 349. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 356. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 363. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 370. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 377. In some embodiments, the LCDR1 comprises an amino acid sequence set forth in SEQ ID NO: 384.

[0079] In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at leastWSGR Docket No. 67237-702.60186%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1, 8, 15, 22, 29, 36, 42, 46, 53, 60, 65, 72, 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, 162, 169, 176, 183, 190, 197, 204, 211, 218, 225, 232, 239, 246, 253, 260, 267, 274, 281, 288, 295, 302, 309, 316, 323, 330, 337, 344, 351, 358, 365, 372, or 379. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 15. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 22. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 42. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 46. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 60. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 65. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 99. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 106. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 113. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 120. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 127. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 134. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQWSGR Docket No. 67237-702.601ID NO: 141. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 148. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 155. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 169. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 176. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 183. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 190. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 197. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 204. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 211. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 218. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 225. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 232. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 239. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 246. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 253. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 260. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 267. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 274. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 281. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 288. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 295. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 302. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 309. In some embodiments, the heavy chain comprises aWSGR Docket No. 67237-702.601variable region comprising an amino acid sequence set forth in SEQ ID NO: 316. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 323. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 330. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 337. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 344. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 351. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 358. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 365. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 372. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 379.

[0080] In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 5, 12, 19, 26, 33, 40, 44, 50, 57, 62, 69, 76, 89, 96, 103, 110, 117, 124, 131, 138, 145, 152, 159, 166, 173, 180, 187, 194, 201, 208, 215, 222, 229, 236, 243, 250, 257, 264, 271, 278, 285, 292, 299, 306, 313, 320, 327, 334, 341, 348, 355, 362, 369, 376, or 383. In some embodiments, the light comprises an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 12. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 40. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 44. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 50. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 57. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 62. In someWSGR Docket No. 67237-702.601embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 69. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 89. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 103. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 110. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 117. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 124. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 131. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 138. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 145. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 152. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 159. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 166. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 173. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 180. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 187. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 194. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 201. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 208. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 215. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 222. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 229. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 236. In some embodiments, the light chain comprises a variable region comprising an amino acidWSGR Docket No. 67237-702.601sequence set forth in SEQ ID NO: 243. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 250. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 257. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 264. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 271. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 278. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 285. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 292. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 299. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 306. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 313. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 320. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 327. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 334. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 341. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 348. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 355. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 362. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 369. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 376. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence set forth in SEQ ID NO: 383.

[0081] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the heavy chain comprises a HCDR1 comprising anWSGR Docket No. 67237-702.601amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of WAS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO 6. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 5.

[0082] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 11. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of GTS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 8. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 12.WSGR Docket No. 67237-702.601

[0083] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of YAS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO 20. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 15. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 19.

[0084] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 25. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 24. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 23. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 28. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of NAK. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequenceWSGR Docket No. 67237-702.601identity to SEQ ID NO: 22. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 26.

[0085] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 30. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 35. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of RVN. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 34. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 29. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 33.

[0086] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 39. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 38. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of GTS. In some embodiments, the light chainWSGR Docket No. 67237-702.601comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 36. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 40.

[0087] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 43. the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3. the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2. the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 45. the light chain comprises a LCDR2 comprising an amino acid sequence of WAS. the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 6. the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 42. the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 44.

[0088] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 49. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 48. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 47. In some embodiments, the antibody or bindingWSGR Docket No. 67237-702.601fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of YAS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 51. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 46. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 50.

[0089] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 55. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of YTS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 53. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 57.

[0090] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In someWSGR Docket No. 67237-702.601embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 61. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of WAS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 63. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 60. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 62.

[0091] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 67. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 71. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of WAS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 70. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 65. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% atWSGR Docket No. 67237-702.601least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 69.

[0092] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 75. In some embodiments, the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 74. In some embodiments, the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 78. In some embodiments, the light chain comprises a LCDR2 comprising an amino acid sequence of TVS. In some embodiments, the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 77. In some embodiments, the heavy chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 72. In some embodiments, the light chain comprises a variable region comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 76.

[0093] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in any one of SEQ ID NOs: 1, 8, 15, 22, 29, 36, 42, 46, 53, 60, 65, or 72 and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%WSGR Docket No. 67237-702.601sequence identity to an amino acid sequence set forth in any one of SEQ ID NOs: 5, 12, 19, 26, 33, 40, 44, 50, 57, 62, 69, or 76.

[0094] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 1; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5.

[0095] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 12.

[0096] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 15; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at leastWSGR Docket No. 67237-702.60190%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 19.

[0097] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 22; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 26.

[0098] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 29; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO:33.

[0099] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 36; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at leastWSGR Docket No. 67237-702.60170%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 40.

[0100] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 42; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 44.

[0101] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 46; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 50.

[0102] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53;WSGR Docket No. 67237-702.601and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 57.

[0103] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 60; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 62.

[0104] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 65; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 69.

[0105] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, atWSGR Docket No. 67237-702.601least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72; and (b) a light chain comprising an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 76.

[0106] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a HCDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4, 11, 18, 25, 32, 39, 43, 49, 56, 61, 68, or 75, (b) a HCDR2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 48, 55, 67, or 74, and (c) a HCDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 47, 54, 66, or 73. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 7, 14, 21, 28, 35, 45, 52, 59, 64, 71, or 78, (b) a LCDR2 comprising an amino acid sequence selected from WAS, GTS, YAS, NAK, RVN, YTS, or TVS, and (c) a LCDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6, 13, 20, 27, 34, 41, 51, 58, 63, 70, or 77.

[0107] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 4; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 7; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 6.

[0108] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 11; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 10; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 14; a LCDR2 comprising an amino acid sequence of GTS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 13.

[0109] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 18; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 17; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 21; a LCDR2 comprising an amino acid sequence of YAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 20.

[0110] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 25; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 24; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 23. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 28; a LCDR2 comprising an amino acid sequence of NAK; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 27.[OHl] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 32; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 31; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 30. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 35; a LCDR2 comprising an amino acid sequence of RVN; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 34.

[0112] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 39; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 38; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, the antibody or theWSGR Docket No. 67237-702.601binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14; a LCDR2 comprising an amino acid sequence of GTS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 41.

[0113] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 43; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 45; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 6.

[0114] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 49; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 48; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 47. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 52; a LCDR2 comprising an amino acid sequence of YAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 51.

[0115] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 56; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 55; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 59; a LCDR2 comprising an amino acid sequence of YTS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 58.

[0116] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 61; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3; and a HCDR1 comprising anWSGR Docket No. 67237-702.601amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 64; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 63.

[0117] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 68; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 67; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 71; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 70.

[0118] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 75; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 74; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 78; a LCDR2 comprising an amino acid sequence of TVS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 77.

[0119] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 1; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 5.

[0120] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 8; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 12.

[0121] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chainWSGR Docket No. 67237-702.601comprising an amino acid sequence set forth in SEQ ID NO: 15; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 19.

[0122] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 22; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 26.

[0123] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 29; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO:33.

[0124] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 36; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 40.

[0125] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 42; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 44.

[0126] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 46; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 50.

[0127] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 53; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 57.

[0128] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chainWSGR Docket No. 67237-702.601comprising an amino acid sequence set forth in SEQ ID NO: 60; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 62.

[0129] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 65; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 69.

[0130] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 72; and (b) a light chain comprising an amino acid sequence set forth in SEQ ID NO: 76.

[0131] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 88; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 87; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 86. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 91; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 90. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 85. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 89.

[0132] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 95; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 94; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 93. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 98; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 97. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%,WSGR Docket No. 67237-702.60170%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 92. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 96.

[0133] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 102; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 101; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 105; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 104. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 99. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 103.

[0134] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 109; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 108; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 112; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 111. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 106. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 110.

[0135] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 116; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 115; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 114. In some embodiments, the antibody or theWSGR Docket No. 67237-702.601binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 119; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 118. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 113. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 117.

[0136] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 123; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 122; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 121. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 126; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 125. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 120. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 124.

[0137] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 130; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 129; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 128. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 133; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 132. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 127. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 131.

[0138] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In someWSGR Docket No. 67237-702.601embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 137; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 136; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 135. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 140; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 139. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 134. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 138.

[0139] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 144; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 143; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 142. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 147; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 141. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 145.

[0140] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 151; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 150; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 149. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 154; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 153. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 148. InWSGR Docket No. 67237-702.601some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 152.

[0141] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 158; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 157; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 156. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 161; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 155. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 159.

[0142] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 165; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 164 and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 163. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 168; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 167. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 162. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 166.

[0143] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 172; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 171; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 170. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 175; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 174. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 169. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 173.

[0144] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 179; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 178; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 182; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 181. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 176. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 180.

[0145] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 186; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 185; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 184. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 189; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 188. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 183. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 187.

[0146] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprisingWSGR Docket No. 67237-702.601a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 193; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 192; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 191. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 196; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 195. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 190. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 194.

[0147] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 200; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 199; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 198. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 203; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 202. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 197. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 201.

[0148] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 207; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 206; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 205. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 210; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 209. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 204. InWSGR Docket No. 67237-702.601some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 208.

[0149] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 214; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 213; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 212. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 217; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 216. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 211. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 215.

[0150] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 221; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 220; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 224; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 223. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 218. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 222.

[0151] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 228; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 227; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 226. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 231; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 230. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 225. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 229.

[0152] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 235; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 234; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 233. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 238; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 237. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 232. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 236.

[0153] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 242; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 241; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 240. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 245; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 244. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 239. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 243.

[0154] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprisingWSGR Docket No. 67237-702.601a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 249; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 248; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 247. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 252; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 251. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 246. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 250.

[0155] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 256; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 255; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 254. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 259; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 258. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 253. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 257.

[0156] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 263; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 262; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 261. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 266; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 265. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 260. InWSGR Docket No. 67237-702.601some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 264.

[0157] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 270; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 269; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 268. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 273; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 272. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 267. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 271.

[0158] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 277; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 276; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 275. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 280; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 279. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 278. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 274.

[0159] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 284; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 283; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 282. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 287; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 286. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 281. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 285.

[0160] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 291; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 290; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 289. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 294; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 293. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 288 In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 292.

[0161] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 298; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 297; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 296. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 301; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 300. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 295. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 299.

[0162] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprisingWSGR Docket No. 67237-702.601a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 305; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 304; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 303. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 308; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 307. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 302. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 306.

[0163] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 312; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 311; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 310. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 315; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 314. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 309. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 313.

[0164] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 319; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 318; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 317. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 322; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 321. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 316. InWSGR Docket No. 67237-702.601some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 320.

[0165] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 326; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 325; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 324. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 329; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 328. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 323. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 327.

[0166] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 333; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 332; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 331. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 336; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 335. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 330. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 334.

[0167] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 340; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 339; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 338. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 343; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 342. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 337. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 341.

[0168] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 347; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 346; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 345. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 350; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 349. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 344. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 348.

[0169] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 354; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 353; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 352. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 357; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 356. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 351. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 355.

[0170] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprisingWSGR Docket No. 67237-702.601a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 361; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 360; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 359. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 364; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 363. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 358. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 362.

[0171] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 368; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 367; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 366. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 371; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 370. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 365. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 369.

[0172] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 375; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 374; and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 373. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 378; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 377. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 372. InWSGR Docket No. 67237-702.601some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 376.

[0173] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 382; a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 381 and a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 380. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 385; a LCDR2 comprising an amino acid sequence of WAS; and a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 384. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 379. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 383.

[0174] Also provided herein is a composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the antibody or the binding fragment thereof comprises a heavy chain comprising any one HCDR3 set forth in Table 5; any one HCDR2 set forth in Table 5; and any one HCDR1 set forth in Table 5. In some embodiments, the antibody or the binding fragment thereof comprises a light chain comprising any one LCDR3 set forth in Table 5; any one LCDR2 set forth in Table 5; and any one LCDR1 set forth in Table 5. In some embodiments, the heavy chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to any one heavy chain set forth in Table 5. In some embodiments, the light chain comprises an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to any one light chain set forth in Table 5

[0175] Also provided herein is a composition comprising an scFv which specifically binds to the polymeric immunoglobulin receptor (plgR). In some embodiments, the scFv comprises a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to an scFv set forth in Table 11. In some embodiments, the scFv comprises a light chain comprising an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to any one light chain set forth in Table 5. In some embodiments, the scFv comprises a heavy chain comprising an amino acid sequence having atWSGR Docket No. 67237-702.601least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to any one heavy chain set forth in Table 5.

[0176] In some embodiments, the antibody or the binding fragment thereof of any of the compositions disclosed herein binds to plgR with an affinity of at least O.OlnM, at least 0.05nM, at least O.lnM, at least 0.5nM, at least InM, at least 5 nM, at least lOnM, at least 20nM, at least 30nM, at least 40nM, at least 50nM, at least 60nM, at least 70nM, at least 80nM, at least 90nM, at least lOOnM, at least 200nM, at least 400nM, at least 600nM, at least 800nM, at least IpM, at least 5pM, at least lOpM, at least 20pM, at least 30pM, at least 40pM, at least 50pM, at least 60pM, at least 70pM, at least 80pM, at least 90pM, at least lOOpM, or more. In some embodiments, the antibody or the binding fragment thereof of any of the compositions disclosed herein binds to plgR with an affinity of at most O.OlnM, at most 0.05nM, at most 0. InM, at most 0.5nM, at most InM, at most 5 nM, at most lOnM, at most 20nM, at most 30nM, at most 40nM, at most 50nM, at most 60nM, at most 70nM, at most 80nM, at most 90nM, at most lOOnM, at most 200nM, at most 400nM, at most 600nM, at most 800nM, at most IpM, at most 5pM, at most lOpM, at most 20 pM, at most 30pM, at most 40 pM, at most 50pM, at most 60 pM, at most 70pM, at most 80pM, at most 90pM, at most lOOpM, or more. In some embodiments, the antibody or the binding fragment thereof of any of the compositions disclosed herein binds to plgR with an affinity of about O.OlnM, about 0.05nM, about O.lnM, about 0.5nM, about InM, about 5 nM, about lOnM, about 20nM, about 30nM, about 40nM, about 50nM, about 60nM, about 70nM, about 80nM, about 90nM, about lOOnM, about 200nM, about 400nM, about 600nM, about 800nM, about IpM, about 5pM, about lOpM, about 20pM, about 30pM, about 40pM, about 50pM, about 60pM, about 70pM, about 80pM, about 90pM, about lOOpM, or more.

[0177] In some embodiments, the composition is capable of inducing transcytosis via the activity of plgR. In some embodiments, when contacted to plgR, the antibody or the binding fragment thereof exhibits an increase in transcytosis by at least 0.5%, at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 200%, at least 300%, or more compared to an antibody that is not specific for plgR.

[0178] In some embodiments, when contacted to an endothelial barrier expressing plgR, the antibody or the binding fragment thereof exhibits an increase in transcytosis by at least 0.5%, at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 200%, at least 300%, or moreWSGR Docket No. 67237-702.601compared to an antibody that is not specific for plgR. In some embodiments, when contacted to an epithelial barrier expressing plgR, the antibody or the binding fragment thereof exhibits an increase in transcytosis by at least 0.5%, at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 200%, at least 300%, or more compared to an antibody that is not specific for plgR

[0179] In some embodiments, the antibody or the binding fragment thereof is an scFv. In some embodiments, the antibody or the binding fragment thereof is a sdAb. In some embodiments, the antibody or the binding fragment thereof is a Fab. In some embodiments, the antibody or the binding fragment thereof is a VHH.

[0180] In some embodiments, the antibody or the binding fragment thereof is an IgG molecule. In some embodiments, the antibody or the binding fragment thereof is an IgGl molecule. In some embodiments, the antibody or the binding fragment thereof is an IgG2 molecule. In some embodiments, the antibody or the binding fragment thereof is an IgG2a molecule. In some embodiments, the antibody or the binding fragment thereof is an IgG2b molecule. In some embodiments, the antibody or the binding fragment thereof is an IgG2c. In some embodiments, the antibody or binding fragment thereof is an IgG3 molecule. In some embodiments, the antibody or binding fragment thereof is an IgG4 molecule. In some embodiments the IgG molecule is a mouse IgG molecule. In some embodiments, the IgG molecule is a human IgG molecule. In some embodiments, the IgG molecule is a human IgGl (hlgGl) molecule. In some embodiments, the hlgGl comprises one or more mutations. In some embodiments, the one or more mutations are selected from the group consisting of L234A, L235A, P329G (e.g., in the hlgGl heavy chain) and any combination thereof. In some embodiments, the one or more mutations result in a reduction in Fc activity of the IgG molecule compared to an otherwise identical IgG molecule which does not comprise the one or more mutations. In some embodiments, the antibody or the binding fragment is cl ass- switched to from one IgG subtype to another IgG subtype. In some embodiments, the antibody or binding fragment is class switched to IgGl, e.g., human IgGl (hlgGl). In some embodiments, the antibody or binding fragment retain at least 80%, at least 90%, at least 95%, or at least 100% antigen specificity after class switching. In some embodiments, the antibody or the binding fragment thereof comprises a constant region having an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQWSGR Docket No. 67237-702.601ID NO: 80 or 81. In some embodiments, the antibody or the binding fragment thereof comprises a constant region having an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the antibody or the binding fragment thereof comprises a constant region having an amino acid sequence with at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 81.

[0181] In some embodiments, the antibody or the binding fragment thereof comprises a constant region, e.g., an IgGl constant region. In some embodiments the constant region comprises one or more mutation, e.g., one or more mutation selected from an L234A, L235A, and P329G (LALAPG) mutation in the IgGl heavy chain, e.g., in the hlgGl heavy chain. In some embodiments, a constant region comprising one or more mutation, e.g., one or more mutation selected from an L234A, L235A, and P329G (LALAPG) mutation in the IgGl heavy chain, e.g., in the hlgGl heavy chain has reduced Fc function compared to an IgGl constant region lacking any mutation. In some embodiments, the LALAPG mutation in the IgGl heavy chain, e.g., in the hlgGl heavy chain results in a reduction in Fc activity of 0.5%, at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 200%, at least 300%, or more compared to an otherwise identical antibody which does not comprise the LALAPG mutation. In some embodiments, the constant region is an IgGl constant region, e.g., a human IgGl constant region, e.g., a human IgGl constant region comprising an amino acid sequence as set forth in SEQ ID NO: 80 or 81. In some embodiments, the constant region is a human constant region. In some embodiments, an hlgGl heavy chain constant region disclosed herein comprises an amino acid sequence as set forth in SEQ ID NO: 80 or 81.MGWSCIILFLVATATGVHSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPI EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYWSGR Docket No. 67237-702.601 KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 80) (signal peptide indicated with underline; mutations indicated in bold).

[0182] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP EAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81) (mutations indicated in bold).

[0183] In some embodiments, the antibody or the binding fragment thereof comprises a kappa constant region, e.g., a human kappa constant region comprising an amino acid sequence as set forth in SEQ ID NO: 82, 83, or 386.

[0184] MGWSCIILFLVATATGVHSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQG LSSPVTKSFNRGEC (SEQ ID NO: 82) (signal peptide indicated with underline).

[0185] RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83).

[0186] KLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO: 386).

[0187] In some embodiments, a IgGl constant region, e.g., a hlgGl constant region or a kappa constant region disclosed herein comprises a signal peptide. In some embodiments, a IgGl constant region or a kappa constant region disclosed herein lacks a signal peptide. In some embodiments, a signal peptide can comprise an amino acid sequence of MGWSCIILFLVATATGVHS (SEQ ID NO: 84). Exemplary sequences of different signal peptides are provided in Table 7. In some embodiments, a signal peptide can comprise an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 80% at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any one amino acid sequence set forth in Table 7.

[0188] In some embodiments, the antibody or binding fragment thereof is conjugated to a therapeutic payload.

[0189] In some embodiments, an antibody or binding fragment thereof described herein is modified to improve functionality. In some embodiments, the modification is a functionalWSGR Docket No. 67237-702.601maturation, e.g., a functional maturation resulting in improved antibody function; e.g., improved specificity, improved affinity for the target, improved avidity for the target, decreased immunogenicity, improved stability, e.g., thermostability, improved antibody cross-reactive binding (e.g., cross-reactive binding to the same immunogen in different species or cross-reactive binding to structurally similar immunogen), improved blocking activity, improved epitope binding, improved antibody-on-antibody cross-competition and / or improved safety profile compared to an antibody that is not modified. In some embodiments, a functional maturation may comprise a modification in the antibody's heavy chain constant region. In some embodiments, a functional maturation may result in isotype switching. In some embodiments, a functional maturation may comprise V(D)J recombination. In some embodiments, a functional maturation may comprise somatic hypermutation. In some embodiments, the modification is a humanization of the antibody sequence. In some embodiments, the antibody or binding fragment thereof is affinity matured. In some embodiments, the modification can result in but are not limited to one or more of improved specificity, improved affinity for the target, improved avidity for the target, decreased immunogenicity, improved stability, e.g., thermostability, improved antibody cross-reactive binding (e.g., cross-reactive binding to the same immunogen in different species or cross-reactive binding to structurally similar immunogen), improved blocking activity, improved epitope binding, improved antibody-on-antibody cross-competition and / or improved safety profile compared to an antibody that is not modified. In some embodiments, a modified antibody has improved pharmacokinetics, e.g., a prolonged therapeutic effect that is exerted with a less frequency of administration, and immunogenicity, safety, and physicochemical properties (stability and homogeneity) compared to an antibody that is not modified.

[0190] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved specificity to a target compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold increased binding specificity to a target compared to an antibody that is not modified.

[0191] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, atWSGR Docket No. 67237-702.601least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved affinity for a target compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2-fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold higher binding affinity to a target compared to an antibody that is not modified.

[0192] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved avidity for a target compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2-fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold higher avidity compared to an antibody that is not modified.

[0193] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% decreased immunogenicity compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold lower immunogenicity compared to an antibody that is not modified.

[0194] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved stability compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold higher stability compared to an antibody that is not modified.

[0195] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, atWSGR Docket No. 67237-702.601least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved blocking activity compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold higher blocking activity compared to an antibody that is not modified.

[0196] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved epitope binding compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold higher epitope binding compared to an antibody that is not modified.

[0197] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved antibody-on-antibody cross-competition compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved antibody-on-antibody cross-competition compared to an antibody that is not modified.

[0198] In some embodiments, an antibody described herein is a modified antibody. In some embodiments, a modified antibody may have an improved specificity compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved affinity for the target compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved immunogenicity compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved stability, e.g., thermostability compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved safety profile compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved antibody cross-reactive binding compared to an antibody that is not modified. In some embodiments, a modified antibody mayWSGR Docket No. 67237-702.601have an improved blocking activity compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved epitope binding compared to an antibody that is not modified. In some embodiments, a modified antibody may have an improved antibody-on-antibody cross-competition compared to an antibody that is not modified.

[0199] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved specificity compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved specificity compared to an antibody that is not modified.

[0200] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved affinity for the target compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved affinity for the target compared to an antibody that is not modified.

[0201] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% reduced immunogenicity compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold reduced immunogenicity compared to an antibody that is not modified.

[0202] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at leastWSGR Docket No. 67237-702.601600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved stability compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved stability compared to an antibody that is not modified.

[0203] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% antibody cross-reactive binding compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold antibody cross-reactive binding compared to an antibody that is not modified.

[0204] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved blocking activity compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved blocking activity compared to an antibody that is not modified.

[0205] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved epitope binding compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved epitope binding compared to an antibody that is not modified.

[0206] In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, atWSGR Docket No. 67237-702.601least 100%, at least 150%, at least 200%, at least 300%, at least 400%, at least 500%, at least 600%, at least 700%, at least 800%, at least 900%, or at least 1000% improved antibody-on-antibody cross-competition compared to an antibody that is not modified. In some embodiments, a modified antibody has at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold improved antibody-on-antibody cross-competition compared to an antibody that is not modified.

[0207] In some embodiments, the antibody is functionally matured. Functional maturation can include but are not limited to somatic hypermutation, affinity maturation, and Class switch recombination (CSR). In some embodiments, an antibody disclosed herein is a codon optimized antibody. In some embodiments, an antibody disclosed herein is a humanized antibody.

[0208] In some embodiments, a modified antibody has one or more alteration in the amino acid sequence of the light chain region, e.g., in a light chain CDR, compared to an antibody that is not modified. In some embodiments, a modified antibody has one or more alteration in the amino acid sequence of the heavy chain region, e.g., in a heavy chain CDR compared to an antibody that is not modified. In some embodiments, a modified antibody has one or more alteration in the amino acid sequence of the Fc receptor domain, compared to an antibody that is not modified. An alteration can include for example, deletion, insertion and / or substitution of one or more amino acid sequence residues of the antibody.Nucleic Acids and Vectors

[0209] Also provided herein are nucleic acids (e.g., a polynucleotide, an oligonucleotide) encoding any of the antibodies or the binding fragments thereof disclosed herein. In some embodiments, the nucleic acid is codon optimized.

[0210] The terms "polynucleotide," "oligonucleotide," and "nucleic acid" are used interchangeably to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof, either in single-, double-, or multistranded form. A polynucleotide may be exogenous or endogenous to a cell. A polynucleotide may exist in a cell-free environment. A polynucleotide may be a gene or fragment thereof. A polynucleotide may be DNA. A polynucleotide may be RNA. A polynucleotide may have any three-dimensional structure, and may perform any function, known or unknown.

[0211] A polynucleotide may comprise one or more analogs (e.g., altered backbone, sugar, or nucleobase). If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. Some non-limiting examples of modified nucleotides or analogs include: pseudouridine, 5 -bromouracil, 5-methylcytosine, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, florophores (e.g. rhodamine or fluorescein linkedWSGR Docket No. 67237-702.601to the sugar), thiol containing nucleotides, biotin linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudourdine, dihydrouridine, queuosine, and wyosine. Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, eDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes, and primers. The sequence of nucleotides may be interrupted by non-nucleotide components.

[0212] Also provided herein are vectors comprising any of the nucleic acids disclosed herein. The term "vector" refers to a nucleic acid molecule capable of transporting or mediating expression of a heterologous nucleic acid. A "vector sequence" as used herein, refers to a sequence of nucleic acid comprising at least one origin of replication and at least one selectable marker gene. Vectors capable of directing the expression of genes and / or nucleic acid sequence to which they are operatively linked are referred to herein as "expression vectors".

[0213] A plasmid is a species of the genus encompassed by the term "vector." In general, expression vectors of utility are often in the form of "plasmids" which refer to circular double stranded DNA molecules which, in their vector form are not bound to the chromosome, and typically comprise entities for stable or transient expression of the encoded DNA. Other expression vectors that can be used in the methods as disclosed herein include, but are not limited to plasmids, episomes, bacterial artificial chromosomes, yeast artificial chromosomes, bacteriophages or viral vectors, and such vectors can integrate into the host's genome or replicate autonomously in the cell. A vector can be a DNA or RNA vector. Other forms of expression vectors known by those skilled in the art which serve the equivalent functions can also be used, for example, self-replicating extrachromosomal vectors or vectors capable of integrating into a host genome. Exemplary vectors are those capable of autonomous replication and / or expression of nucleic acids to which they are linked.

[0214] Also disclosed herein is a cell, comprising (a) any of the antibodies or the binding fragments thereof disclosed herein, (b) any of the fusion proteins disclosed herein, (c) any of the nucleic acids disclosed herein, or (d) any of the vectors disclosed herein.

[0215] Disclosed herein is a composition, comprising (a) any of the antibodies or the binding fragments thereof disclosed herein, (b) any of the fusion proteins disclosed herein, (c) any of the nucleic acids disclosed herein, (d) any of the vectors disclosed herein, or (e) any of the cells disclosed herein.WSGR Docket No. 67237-702.601Pharmaceutical Compositions

[0216] Provided herein is a pharmaceutical composition comprising (a) any of the antibodies or the binding fragments thereof disclosed herein, any of the fusion proteins disclosed herein, any of the nucleic acids disclosed herein, any of the vectors disclosed herein, any of the cells disclosed herein, or any of the compositions disclosed herein, and (b) a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable” refers to approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia (U.S.P.) or other generally recognized pharmacopeia for use in animals, including humans. A “pharmaceutically acceptable carrier” refers to a carrier that can be administered to a subject, together with an active moiety, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the moiety.

[0217] The pharmaceutical compositions disclosed herein can be administered via any route known in the art. In some embodiments, the pharmaceutical composition is administered via a parenteral administration route. In some embodiments, the pharmaceutical composition is administered via intramuscular administration route. In some embodiments, the pharmaceutical composition is administered via intravenous administration route. In some embodiments, the pharmaceutical composition is administered via subcutaneous administration route. In some embodiments, the pharmaceutical composition is administered via peritoneal administration route.Methods of Treatment

[0218] The antibodies or the binding fragments, fusion proteins, nucleic acids, vectors, cells, compositions, or pharmaceutical compositions described herein can be utilized in the treatment of cancers. In one aspect, provided herein are methods of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of the antibodies or the binding fragments, fusion protein, nucleic acid, vector, cell, composition, or pharmaceutical composition. In some embodiments, the cancer has a closed apical lumen microarchitecture. In some embodiments, the cancer is a primary cancer. In some embodiments, the cancer is metastatic. In some embodiments, the cancer is locally invasive. In some embodiments, the cancer is a local recurrence. In some embodiments, the cancer is a locally relapsed cancer. In some embodiments, the size of the cancer is decreased or inhibited. In some embodiments, the growth of the cancer is decreased or inhibited. In some embodiments, the viability of the cancer is decreased or inhibited. In some embodiments, the cancer to be treated expresses plgR. In some embodiments, the cancer is an adenocarcinoma. In some embodiments, the cancer is a colorectal cancer. In some embodiments, the cancer is a pancreatic cancer. In some-n-WSGR Docket No. 67237-702.601embodiments, the cancer is a gastric cancer. In some embodiments, the cancer is an esophageal cancer. In some embodiments, the cancer is a kidney cancer. In some embodiments, the cancer is an endometrial cancer. In some embodiments, the cancer is a cervical cancer. In some embodiments, the cancer is a breast cancer. In some embodiments, the cancer is a prostate cancer. In some embodiments, the cancer is a urinary bladder cancer. In some embodiments, the cancer is a cancer of the head and neck. In some embodiments, the cancer is a liver cancer. In some embodiments, the cancer is a gallbladder cancer. In some embodiments, the cancer is an ovarian cancer. In some embodiments, the cancer is a non-small cell lung cancer.Certain Definitions

[0219] All terms are intended to be understood as they would be understood by a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains.

[0220] The following definitions supplement those in the art and are directed to the current application and are not to be imputed to any related or unrelated case, e.g., to any commonly owned patent or application. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present disclosure, the preferred materials and methods are described herein. Accordingly, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0221] The terminology used herein is for the purpose of describing particular cases only and is not intended to be limiting. In this application, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0222] In this application, the use of “or” means “and / or” unless stated otherwise. The terms “and / or” and “any combination thereof’ and their grammatical equivalents as used herein, can be used interchangeably. These terms can convey that any combination is specifically contemplated. Solely for illustrative purposes, the following phrases “A, B, and / or C” or “A, B, C, or any combination thereof’ can mean “A individually; B individually; C individually; A and B; B and C; A and C; and A, B, and C.” The term “or” can be used conjunctively or disjunctively unless the context specifically refers to a disjunctive use.

[0223] The term “about” or “approximately” can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per theWSGR Docket No. 67237-702.601practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 15%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, or within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.

[0224] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure.

[0225] Reference in the specification to “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures. To facilitate an understanding of the present disclosure, a number of terms and phrases are defined below.

[0226] Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, as well as all intervening decimal values between the aforementioned integers such as, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. With respect to sub-ranges, “nested sub-ranges” that extend from either end point of the range are specifically contemplated. For example, a nested sub-range of an exemplary range of 1 to 50 may comprise 1 to 10, 1 to 20, 1 to 30, and 1 to 40 in one direction, or 50 to 40, 50 to 30, 50 to 20, and 50 to 10 in the other direction.

[0227] The term “subject” refers to an animal which is the object of treatment, observation, or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, bovine, equine, canine, ovine, or feline.

[0228] A plgR binder as defined herein is said to be “specific for” or “selectively binds to” plgR with an affinity that is at least 5 times, at least 10 times, at least 25 times, least 50WSGR Docket No. 67237-702.601times, least 100 times, etc., better than the affinity with which a non-specific binder binds to plgR. Binders may comprise antibodies or fragments of antibodies.

[0229] A plgR agonist as defined herein is said to be “specific for” or “selectively binds to” plgR and induces transcytosis of the agonist in a basal to apical direction.

[0230] A “conjugate” as defined herein is said to be a product of a covalent linking reaction joining an agonist for plgR and a therapeutic payload, or a binder for plgR and a therapeutic payload. The term “antibody” refers to a class of proteins that are generally known as immunoglobulins, including, but not limited to IgGl, IgG2, IgG3, and IgG4), IgA (including IgAl and IgA2), IgD, IgE, IgM, and IgY. The term “antibody” includes, but is not limited to, full length antibodies and antigen-binding fragments such as, for example, single-domain antibodies (sdAb), single chain fragment variable (scFv), fragment antigen-binding region (Fab), or VHH. An “antibody” can be non-naturally occurring.

[0231] The term “microarchitecture” or “architecture” as used herein are used interchangeably and are said to be the structure and arrangement of a tissue which includes but is not limited to a cancer and its metastases. A “closed apical lumen” refers to a tissue structure that includes a lumen or opening completely enclosed by cells with the apical face of said cells being exposed to the lumen or opening.

[0232] “Polarity” or “apical and basal polarity” as used herein refers to the property of a cell or tissue to have different characteristics at the apical or lumen-facing end compared to the basal or basement membrane-facing end. Different characteristics include but are not limited to types of proteins expressed, quantities of proteins expressed, and structural differences such presence of cilial structures.

[0233] The term “metastasis” as used herein are said to refer to the development of secondary cancers apart from the primary cancer. This includes but is not limited to secondary cancers that may be in the process of forming from the primary cancer, secondary cancers near the primary cancer, and secondary cancers that have developed further and may be in a disparate region of the same tissue as the primary cancer or in a different tissue or organ entirely.“Micrometastasis” refers to a small metastasis, e.g., having a size less than about 5mm. The term “locally invasive” refers to a secondary cancer that has arisen near the primary cancer. This includes but is not limited to a secondary cancer within the same tissue as the primary cancer. This includes but is not limited to a secondary cancer within a different tissue near to the primary cancer.NUMBERED EMBODIMENTS

[0234] Embodiment 1. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein theWSGR Docket No. 67237-702.601antibody or the binding fragment thereof comprises a heavy chain comprising a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4, 11, 18, 25, 32, 39, 43, 49, 56, 61, 68, or 75.

[0235] Embodiment 2. The composition of embodiment 1, wherein the heavy chain comprises a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 48, 55, 67, or 74.

[0236] Embodiment 3. The composition of embodiment 1 or 2, wherein the heavy chain further comprises a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 47, 54, 66, or 73.

[0237] Embodiment 4. The composition of any one of embodiments 1-3, wherein the antibody or binding fragment thereof comprises a light chain comprising a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 7, 14, 21, 28, 35, , 45, 52, 59, 64, 71, or 78.

[0238] Embodiment 5. The composition of embodiment 4, wherein the light chain comprises a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from WAS, GTS, YAS, NAK, RVN, YTS, or TVS.

[0239] Embodiment 6. The composition of embodiment 4 or 5, wherein the light chain comprises a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6, 13, 20, 27, 34, 41, 51, 58, 63, 70, or 77.

[0240] Embodiment 7. The composition of any one of embodiments 1-6, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to any one of SEQ ID NOs: 1, 8, 15, 22, 29, 36, 42, 46, 53, 60, 65, or 72.

[0241] Embodiment 8. The composition of any one of embodiments 4-7, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to any one of SEQ ID NOs: 5, 12, 19, 26, 33, 40, 44, 50, 57, 62, 69, or 76.

[0242] Embodiment 9. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 4.

[0243] Embodiment 10. The composition of embodiment 9, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3.

[0244] Embodiment 11. The composition of embodiment 9 or 10, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2.WSGR Docket No. 67237-702.601

[0245] Embodiment 12. The composition of any one of embodiments 9-11, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 7.

[0246] Embodiment 13. The composition of embodiment 12, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of WAS.

[0247] Embodiment 14. The composition of embodiment 12 or 13, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO 6.

[0248] Embodiment 15. The composition of any one of embodiments 9-14, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 1.

[0249] Embodiment 16. The composition of any one of embodiments 12-15, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 5.

[0250] Embodiment 17. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 11.

[0251] Embodiment 18. The composition of embodiment 17, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 10.

[0252] Embodiment 19. The composition of embodiment 17 or 18, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 9.

[0253] Embodiment 20. The composition of any one of embodiments 17-19, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14.

[0254] Embodiment 21. The composition of embodiment 19, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of GTS.

[0255] Embodiment 22. The composition of embodiment 19 or 21, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 13.

[0256] Embodiment 23. The composition of any one of embodiments 17-22, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 8.

[0257] Embodiment 24. The composition of any one of embodiments 19-23, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 12.WSGR Docket No. 67237-702.601

[0258] Embodiment 25. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 18.

[0259] Embodiment 26. The composition of embodiment 25, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 17.

[0260] Embodiment 27. The composition of embodiment 25 or 26, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 16.

[0261] Embodiment 28. The composition of any one of embodiments 25-27, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 21.

[0262] Embodiment 29. The composition of embodiment 28, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of YAS.

[0263] Embodiment 30. The composition of embodiment 28 or 29, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO 20.

[0264] Embodiment 31. The composition of any one of embodiments 25-30, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 15.

[0265] Embodiment 32. The composition of any one of embodiments 28-31, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 19.

[0266] Embodiment 33. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 25.

[0267] Embodiment 34. The composition of embodiment 33, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 24.

[0268] Embodiment 35. The composition of embodiment 33 or 34, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 23.

[0269] Embodiment 36. The composition of any one of embodiments 33-35, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 28.

[0270] Embodiment 37. The composition of embodiment 36, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of NAK.WSGR Docket No. 67237-702.601

[0271] Embodiment 38. The composition of embodiment 36 or 37, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 27.

[0272] Embodiment 39. The composition of any one of embodiments 33-38, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 22.

[0273] Embodiment 40. The composition of any one of embodiments 36-39, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 26.

[0274] Embodiment 41. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 32.

[0275] Embodiment 42. The composition of embodiment 41, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 31.

[0276] Embodiment 43. The composition of embodiment 41 or 42, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 30.

[0277] Embodiment 44. The composition of any one of embodiments 41-43, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 35.

[0278] Embodiment 45. The composition of embodiment 44, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of RVN.

[0279] Embodiment 46. The composition of embodiment 44 or 45, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 34.

[0280] Embodiment 47. The composition of any one of embodiments 41-46, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 29.

[0281] Embodiment 48. The composition of any one of embodiment 45-47, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 33.

[0282] Embodiment 49. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 39.

[0283] Embodiment 50. The composition of embodiment 49, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 38.WSGR Docket No. 67237-702.601

[0284] Embodiment 51. The composition of embodiment 49 or 50, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 37.

[0285] Embodiment 52. The composition of any one of embodiments 49-51, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14.

[0286] Embodiment 53. The composition of embodiment 52, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of GTS.

[0287] Embodiment 54. The composition of embodiment 52 or 53, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 41.

[0288] Embodiment 55. The composition of any one of embodiments 49-54, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 36.

[0289] Embodiment 56. The composition of any one of embodiments 52-55, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 40.

[0290] Embodiment 57. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 43.

[0291] Embodiment 58. The composition of embodiment 57, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3.

[0292] Embodiment 59. The composition of embodiment 57 or 58, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2.

[0293] Embodiment 60. The composition of any one of embodiments 57-59, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 45.

[0294] Embodiment 61. The composition of embodiment 60, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of WAS.

[0295] Embodiment 62. The composition of embodiment 60 or 61, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 6.

[0296] Embodiment 63. The composition of any one of embodiments 57-62, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 42.WSGR Docket No. 67237-702.601

[0297] Embodiment 64. The composition of any one of embodiments 60-63, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 44.

[0298] Embodiment 65. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 49.

[0299] Embodiment 66. The composition of embodiment 65, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 48.

[0300] Embodiment 67. The composition of embodiment 65 or 66, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 47.

[0301] Embodiment 68. The composition of any one of embodiments 65-67, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 52.

[0302] Embodiment 69. The composition of embodiment 68, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of YAS.

[0303] Embodiment 70. The composition of 68 or 69, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 51.

[0304] Embodiment 71. The composition of any one of embodiments 65-70, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 46.

[0305] Embodiment 72. The composition of any one of embodiments 68-71, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 50.

[0306] Embodiment 73. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 56.

[0307] Embodiment 74. The composition of embodiment 73, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 55.

[0308] Embodiment 75. The composition of embodiment 73 or 74, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 54.

[0309] Embodiment 76. The composition of any one of embodiments 73-75, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 59.WSGR Docket No. 67237-702.601

[0310] Embodiment 77. The composition of embodiment 76, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of YTS.

[0311] Embodiment 78. The composition of embodiment 76 or 77, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 58.

[0312] Embodiment 79. The composition of any one of embodiments 73-78, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 53.

[0313] Embodiment 80. The composition of any one of embodiments 76-79, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 57.

[0314] Embodiment 81. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 61.

[0315] Embodiment 82. The composition of embodiment 81, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3.

[0316] Embodiment 83. The composition of embodiment 81 or 82, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2.

[0317] Embodiment 84. The composition of any one of embodiments 81-83, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 64.

[0318] Embodiment 85. The composition of embodiment 84, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of WAS.

[0319] Embodiment 86. The composition of embodiment 84 or 85, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 63.

[0320] Embodiment 87. The composition of any one of embodiments 81-86, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 60.

[0321] Embodiment 88. The composition of any one of embodiments 84-87, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 62.

[0322] Embodiment 89. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 68.WSGR Docket No. 67237-702.601

[0323] Embodiment 90. The composition of embodiment 89, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 67.

[0324] Embodiment 91. The composition of embodiment 89 or 90, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 66.

[0325] Embodiment 92. The composition of any one of embodiments 89-91, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 71.

[0326] Embodiment 93. The composition of embodiment 92, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of WAS.

[0327] Embodiment 94. The composition of embodiment 92 or 93, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 70.

[0328] Embodiment 95. The composition of any one of embodiments 89-94, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 65.

[0329] Embodiment 96. The composition of any one of embodiments 92-95, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 69.

[0330] Embodiment 97. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 75.

[0331] Embodiment 98. The composition of embodiment 97, wherein the heavy chain comprises a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 74.

[0332] Embodiment 99. The composition of embodiment 97 or 98, wherein the heavy chain comprises a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 73.

[0333] Embodiment 100. The composition of any one of embodiments 97-99, wherein the antibody or binding fragment thereof comprises a light chain comprising a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 78.

[0334] Embodiment 101. The composition of embodiment 100, wherein the light chain comprises a LCDR2 comprising an amino acid sequence of TVS.

[0335] Embodiment 102. The composition of embodiment 100 or 101, wherein the light chain comprises a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 77.

[0336] Embodiment 103. The composition of any one of embodiments 97-102, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 72.WSGR Docket No. 67237-702.601

[0337] Embodiment 104. The composition of any one of embodiments 100-103, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to SEQ ID NO: 76.

[0338] Embodiment 105. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in any one of SEQ ID NOs: 1, 8, 15, 22, 29, 36, 42, 46, 53, 60, 65, or 72; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in any one of SEQ ID NOs: 5, 12, 19, 26, 33, 40, 44, 50, 57, 62, 69, or 76.

[0339] Embodiment 106. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 1; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5.

[0340] Embodiment 107. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 12.

[0341] Embodiment 108. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 15; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 19.

[0342] Embodiment 109. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 22 and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 26.WSGR Docket No. 67237-702.601

[0343] Embodiment 110. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 29; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33.

[0344] Embodiment 111. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 36; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 40.

[0345] Embodiment 112. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 42; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 44.

[0346] Embodiment 113. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 46; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 50.

[0347] Embodiment 114. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 57.

[0348] Embodiment 115. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ IDWSGR Docket No. 67237-702.601NO: 60; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 62.

[0349] Embodiment 116. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 65; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 69.

[0350] Embodiment 117. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72; and (b) a light chain comprising an amino acid sequence with at least 80% sequence identity to an amino acid sequence set forth in SEQ ID NO: 76.

[0351] Embodiment 118. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4, 11, 18, 25, 32, 39, 43, 49, 56, 61, 68, or 75; (b) a HCDR2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 48, 55, 67, or 74; and (c) a HCDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 47, 54, 66, or 73.

[0352] Embodiment 119. The composition of embodiment 118, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 7, 14, 21, 28, 35, 45, 52, 59, 64, 71, or 78; (b) a LCDR2 comprising an amino acid sequence selected from WAS, GTS, YAS, NAK, RVN, YTS, or TVS; and (c) a LCDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6, 13, 20, 27, 34, 41, 51, 58, 63, 70, or 77.

[0353] Embodiment 120. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 4; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2.

[0354] Embodiment 121. The composition of embodiment 120, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 7; (b) a LCDR2 comprising an amino acid sequence of WAS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 6.

[0355] Embodiment 122. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 11; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 10; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 9.

[0356] Embodiment 123. The composition of embodiment 122, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14; (b) a LCDR2 comprising an amino acid sequence of GTS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 13.

[0357] Embodiment 124. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 18; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 17; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 16.

[0358] Embodiment 125. The composition of embodiment 124, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 21; (b) a LCDR2 comprising an amino acid sequence of YAS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 20.

[0359] Embodiment 126. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 25; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 24; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 23.

[0360] Embodiment 127. The composition of embodiment 126, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 28; (b) a LCDR2 comprising an amino acid sequence of NAK; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 27.

[0361] Embodiment 128. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3WSGR Docket No. 67237-702.601comprising an amino acid sequence set forth in SEQ ID NO: 32; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 31; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 30.

[0362] Embodiment 129. The composition of embodiment 128, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 35; (b) a LCDR2 comprising an amino acid sequence of RVN; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 34.

[0363] Embodiment 130. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 39; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 38; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 37.

[0364] Embodiment 131. The composition of embodiment 130, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 14; (b) a LCDR2 comprising an amino acid sequence of GTS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 41.

[0365] Embodiment 132. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 43; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2.

[0366] Embodiment 133. The composition of embodiment 132, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 45; (b) a LCDR2 comprising an amino acid sequence of WAS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 6.

[0367] Embodiment 134. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 49; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 48; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 47.

[0368] Embodiment 135. The composition of embodiment 134, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an aminoWSGR Docket No. 67237-702.601acid sequence set forth in SEQ ID NO: 52; (b) a LCDR2 comprising an amino acid sequence of YAS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 51.

[0369] Embodiment 136. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 56; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 55; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 54.

[0370] Embodiment 137. The composition of embodiment 136, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 59; (b) a LCDR2 comprising an amino acid sequence of YTS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 58.

[0371] Embodiment 138. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 61; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 3; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 2.

[0372] Embodiment 139. The composition of embodiment 138, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 64; (b) a LCDR2 comprising an amino acid sequence of WAS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 63.

[0373] Embodiment 140. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 68; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 67; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 66.

[0374] Embodiment 141. The composition of embodiment 140, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 71; (b) a LCDR2 comprising an amino acid sequence of WAS; and (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 70.

[0375] Embodiment 142. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising (a) a HCDR3WSGR Docket No. 67237-702.601comprising an amino acid sequence set forth in SEQ ID NO: 75; (b) a HCDR2 comprising an amino acid sequence set forth in SEQ ID NO: 74; and (c) a HCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 73.

[0376] Embodiment 143. The composition of embodiment 142, wherein the antibody or the binding fragment thereof comprises a light chain comprising (a) a LCDR3 comprising an amino acid sequence set forth in SEQ ID NO: 78; (b) a LCDR2 comprising an amino acid sequence of TVS; (c) a LCDR1 comprising an amino acid sequence set forth in SEQ ID NO: 77.

[0377] Embodiment 144. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 1 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 5.

[0378] Embodiment 145. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 8 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 12.

[0379] Embodiment 146. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 15 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 19.

[0380] Embodiment 147. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 22 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 26.

[0381] Embodiment 148. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 29 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 33.

[0382] Embodiment 149. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acidWSGR Docket No. 67237-702.601sequence as set forth in SEQ ID NO: 36 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 40.

[0383] Embodiment 150. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 42 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 44.

[0384] Embodiment 151. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 46 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 50.

[0385] Embodiment 152. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 53 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 57.

[0386] Embodiment 153. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 60 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 62.

[0387] Embodiment 154. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 65 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 69.

[0388] Embodiment 155. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 72 and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 76.

[0389] Embodiment 156. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3WSGR Docket No. 67237-702.601comprising a sequence set forth in SEQ ID NO: 4; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 7; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 6.

[0390] Embodiment 157. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 11; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 10; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 9; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 14; (ii) a LCDR2 comprising a sequence of GTS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 13.

[0391] Embodiment 158. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 18; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 17; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 16; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 21; (ii) a LCDR2 comprising a sequence of YAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 20.

[0392] Embodiment 159. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 25; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 24; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 23; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 28; (ii) a LCDR2 comprising a sequence of NAK; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 27.

[0393] Embodiment 160. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 32; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 31; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 30; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 35;WSGR Docket No. 67237-702.601(ii) a LCDR2 comprising a sequence of RVN; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 34.

[0394] Embodiment 161. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 39; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 38; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 37; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 14; (ii) a LCDR2 comprising a sequence of GTS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 41.

[0395] Embodiment 162. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 43; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 45; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 6.

[0396] Embodiment 163. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 49; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 48; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 47; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 52; (ii) a LCDR2 comprising a sequence of YAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 51.

[0397] Embodiment 164. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 56; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 55; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 54; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 59; (ii) a LCDR2 comprising a sequence of YTS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 58.WSGR Docket No. 67237-702.601

[0398] Embodiment 165. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 61; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 64; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 63.

[0399] Embodiment 166. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 68; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 67; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 66; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 71; (ii) a LCDR2 comprising a sequence of WAS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 70.

[0400] Embodiment 167. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises (a) a heavy chain comprising: (i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 75; (ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 74; (iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 73; and (b) a light chain comprising: (i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 78; (ii) a LCDR2 comprising a sequence of TVS; and (iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 77.

[0401] Embodiment 168. The composition of any one of embodiments 1-167, wherein the antibody or the binding fragment thereof binds to plgR with an affinity of at least InM, at least O.lnM or at least O.OlnM at least IpM, at least lOOnM, or at least 50nM.

[0402] Embodiment 169. The composition of any one of embodiments 1-168, wherein the composition is capable of inducing transcytosis via the activity of plgR.

[0403] Embodiment 170. The composition of any one of embodiments 1-169, wherein, when contacted to plgR, the antibody or the binding fragment thereof exhibits an increase of at least 1%, at least 5%, or at least 10% in transcytosis compared to an antibody that is not specific for plgR.

[0404] Embodiment 171. The composition of any one of embodiments 1-170, wherein the antibody or the binding fragment thereof, when contacted to an endothelial barrier expressingWSGR Docket No. 67237-702.601plgR, exhibits an increase of at least 1%, at least 5%, or at least 10% in transcytosis into the lumen compared to an antibody that is not specific for plgR.

[0405] Embodiment 172. The composition of any one of embodiments 1-170, wherein the antibody or the binding fragment thereof, when contacted to an epithelial barrier expressing plgR, exhibits an increase of at least 1%, at least 5%, or at least 10% in transcytosis into the lumen compared to an antibody that is not specific for plgR.

[0406] Embodiment 173. The composition of any one of embodiments 1-172, wherein the antibody or the binding fragment thereof is an IgG molecule.

[0407] Embodiment 174. The composition of embodiment 173, wherein the IgG molecule is IgGl, IgG2, IgG3, or IgG4.

[0408] Embodiment 175. The composition of embodiment 174, wherein the IgG2 molecule is IgG2a, IgG2b, or IgG2c.

[0409] Embodiment 176. The composition of embodiment 174 or 175, wherein the IgG molecule is a mouse IgG (mlgG) or human IgG molecule (hlgG).

[0410] Embodiment 177. The composition of any one of embodiments 173-176, wherein the IgG molecule is an IgGl molecule.

[0411] Embodiment 178. The composition of embodiment 177, wherein the IgGl molecule is a human IgGl (hlgGl) molecule.

[0412] Embodiment 179. The composition of embodiment 178, wherein the hlgGl comprises one or more mutations.

[0413] Embodiment 180. The composition of embodiment 179, wherein the one or more mutations are selected from the group consisting of L234A, L235A, P329G in the hlgGl heavy chain, and any combination thereof.

[0414] Embodiment 181. The composition of embodiment 179 or 180, wherein the one or more mutations result in a reduction in Fc activity of the IgG molecule compared to an otherwise identical IgG molecule which does not comprise the one or more mutations.

[0415] Embodiment 182. The composition of any one of embodiments 1-181, wherein the antibody or binding fragment thereof comprises a constant region having an amino acid sequence with at least 80% sequence identity to a sequence set forth in SEQ ID NO: 80 or 81.

[0416] Embodiment 183. A nucleic acid encoding the antibody or the binding fragment thereof of any one of embodiments 1-182.

[0417] Embodiment 184. A vector comprising the nucleic acid of embodiment 183.

[0418] Embodiment 185. A cell comprising (a) the antibody or the binding fragment thereof of any one of embodiments 1-182; (b) the nucleic acid of embodiment 183; or (c) the vector of embodiment 184.WSGR Docket No. 67237-702.601

[0419] Embodiment 186. A composition comprising (a) the antibody or the binding fragment thereof of any one of embodiments 1-182; (b) the nucleic acid of embodiment 183; (c) the vector of embodiment 184; or (d) the cell of embodiment 185.

[0420] Embodiment 187. A pharmaceutical composition comprising (a) the antibody or the binding fragment thereof of any one of embodiments 1-182, the nucleic acid of embodiment 183 , the vector of embodiment 184, the cell of embodiment 185, or the composition of embodiment 186 and (b) a pharmaceutically acceptable excipient.

[0421] Embodiment 188. A method of treating a plgR-expressing cancer in a subject in need thereof, the method comprising administering the antibody or the binding fragment thereof of any one of embodiments 1-182, the nucleic acid of embodiment 183, the vector of embodiment 184, the cell of embodiment 185, the composition of embodiment 186, or the pharmaceutical composition of embodiment 187.

[0422] Embodiment 189. A method of treating a metastasis or a local invasion of a plgR-expressing cancer in a subject in need thereof, the method comprising administering the antibody or the binding fragment thereof of any one of embodiments 1-182, the nucleic acid of embodiment 183, the vector of embodiment 184, the cell of embodiment 185, the composition of embodiment 186, or the pharmaceutical composition of embodiment 187.

[0423] Embodiment 190. The method of embodiment 188 or 189, wherein the plgR-expressing cancer is selected from the group consisting of a colorectal cancer, a pancreatic cancer, a gastric cancer, a kidney cancer, an endometrial cancer, a breast cancer, a prostate cancer, a liver cancer, a gallbladder cancer, an ovarian cancer, and a non-small cell lung cancer.EXAMPLES

[0424] The following illustrative examples are representative of embodiments of compositions and methods described herein and are not meant to be limiting in any way.Example 1: Identification of anti-pIgR Antibodies

[0425] To identify antibodies that bind to plgR, recombinant human plgR protein was used to immunize three different mouse strains: BALB / c, NZB / W, and CD1. After immunization, splenic B cells were harvested from the immunized mice and fused with a murine hybridoma cell line (SP2 / 0) to generate three separate fusion libraries, one for each mouse strain.

[0426] From these libraries, 2880 individual clones were selected for screening. Screening for plgR binding was performed using flow cytometry, followed by ELISA binding. In the flow cytometry assay, MDCK cells transduced with a lentivirus to overexpress surface human plgRWSGR Docket No. 67237-702.601were used as target cells. In the ELISA assay, recombinant human plgR protein was used to detect binding by the antibodies. This process is summarized in FIG. 1.

[0427] Out of the 2880 clones, 368 clones that showed positive binding to plgR were tested for transcytosis activity using a TransWell assay. In this assay, candidate antibodies were added to the basal chamber of the TransWell plate. Antibody transport to the apical chamber through a layer of MDCK cells ex...

Claims

WSGR Docket No. 67237-702.601CLAIMS WHAT IS CLAIMED IS:

1. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises a heavy chain comprising a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence set forth in any one of SEQ IDNOs: 4, 11, 18, 25, 32, 39, 43, 49, 56, 61, 68, 75, 88, 95, 102, 109, 116, 123, 130, 137, 144, 151, 158, 165, 172, 179, 186, 193, 200, 207, 214, 221, 228, 235, 242, 249, 256, 263, 270, 277, 284, 291, 298, 305, 312, 319, 326, 333, 340, 347, 354, 361, 368, 375, or 382.

2. The composition of claim 1, wherein the heavy chain comprises a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3, 10, 17, 24, 31, 38, 48, 55, 67, 74, 87, 94, 101, 108, 115, 122, 129, 136, 143, 150, 157, 164, 171, 178, 185, 192, 199, 206, 213, 220, 227, 234, 241, 248, 255, 262, 269, 276, 283, 290, 297, 304, 311, 318, 325, 332, 339, 346, 353, 360, 367, 374, or 381.

3. The composition of claim 1 or 2, wherein the heavy chain further comprises a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 9, 16, 23, 30, 37, 47, 54, 66, 73, 86, 93, 100, 107, 114, 121, 128, 135, 142, 149, 156, 163, 170, 177, 184, 191, 198, 205, 212, 219, 226, 233, 240, 247, 254, 261, 268, 275, 282, 289, 296, 303, 310, 317, 324, 331, 338, 345, 352, 359, 366, 373, or 380.

4. The composition of any one of claims 1-3, wherein the antibody or binding fragment thereof comprises a light chain comprising a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 7, 14, 21, 28, 35, 45, 52, 59, 64, 71, 78, 91, 98, 105, 112, 119, 126, 133, 140, 147, 154, 161, 168, 175, 182, 189, 196, 203, 210, 217, 224, 231, 238, 245, 252, 259, 266, 273, 280, 287, 294, 301, 308, 315, 322, 329, 336, 343, 350, 357, 364, 371, 378, or 385.

5. The composition of claim 4, wherein the light chain comprises a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from WAS, GTS, YAS, NAK, RVN, YTS, or TVS.

6. The composition of claim 4 or 5, wherein the light chain comprises a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6, 13, 20, 27, 34, 41, 51, 58, 63, 70, 77, 90, 97, 104, 111, 118, 125, 132, 139, 146, 153, 160, 167, 174, 181, 188, 195, 202, 209, 216, 223, 230, 237, 244, 251, 258, 265, 272, 279, 286, 293, 300, 307, 314, 321, 328, 335, 342, 349, 356, 363, 370, 377, or 384.WSGR Docket No. 67237-702.6017. The composition of any one of claims 1-6, wherein the heavy chain comprises a variable region comprising an amino acid sequence with at least 80% identity to any one of SEQ IDNOs: 1, 8, 15, 22, 29, 36, 42, 46, 53, 60, 65, 72, 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, 162, 169, 176, 183, 190, 197, 204, 211, 218, 225, 232, 239, 246, 253, 260, 267, 274, 281, 288, 295, 302, 309, 316, 323, 330, 337, 344, 351, 358, 365, 372, or 379.

8. The composition of any one of claims 4-7, wherein the light chain comprises a variable region comprising an amino acid sequence with at least 80% identity to any one of SEQ IDNOs: 5, 12, 19, 26, 33, 40, 44, 50, 57, 62, 69, 76, 89, 96, 103, 110, 117, 124, 131, 138, 145, 152, 159, 166, 173, 180, 187, 194, 201, 208, 215, 222, 229, 236, 243, 250, 257, 264, 271, 278, 285, 292, 299, 306, 313, 320, 327, 334, 341, 348, 355, 362, 369, 376 or 383.

9. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 4;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 7;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 6.

10. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 11;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 10;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 9; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 14;(ii) a LCDR2 comprising a sequence of GTS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 13.

11. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprisesWSGR Docket No. 67237-702.601(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 18;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 17;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 16; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 21;(ii) a LCDR2 comprising a sequence of YAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 20.

12. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 25;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 24;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 23; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 28;(ii) a LCDR2 comprising a sequence of NAK; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 27.

13. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 32;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 31;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 30; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 35;(ii) a LCDR2 comprising a sequence of RVN; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 34.

14. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 39;WSGR Docket No. 67237-702.601(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 38;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 37; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 14;(ii) a LCDR2 comprising a sequence of GTS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 41.

15. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 43;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 45;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 6.

16. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 49;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 48;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 47; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 52;(ii) a LCDR2 comprising a sequence of YAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 51.

17. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 56;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 55;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 54; andWSGR Docket No. 67237-702.601(b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 59;(ii) a LCDR2 comprising a sequence of YTS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 58.

18. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 61;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 3;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 2; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 64;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 63.

19. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 68;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 67;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 66; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 71;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 70.

20. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 75;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 74;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 73; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 78;WSGR Docket No. 67237-702.601(ii) a LCDR2 comprising a sequence of TVS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 77.

21. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 88;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 87;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 86; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 91;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 90.

22. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 95;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 94;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 93; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 98;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 97.

23. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 102;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 101;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 100; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 105;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 104.WSGR Docket No. 67237-702.60124. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 109;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 108;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 107; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 112;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 111.

25. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 116;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 115;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 114; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 119;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 118.

26. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 123;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 122;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 121; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 126;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 125.WSGR Docket No. 67237-702.60127. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 130;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 129;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 128; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 133;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 132.

28. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 137;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 136;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 135; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 140;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 139.

29. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 144;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 143;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 142; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 147;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 146.WSGR Docket No. 67237-702.60130. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 151;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 150;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 149; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 154;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 153.

31. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 158;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 157;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 156; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 161;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 160.

32. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 165;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 164;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 163; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 168;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 167.WSGR Docket No. 67237-702.60133. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 172;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 171;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 170; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 175;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 174.

34. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 179;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 178;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 177; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 182;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 181.

35. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 186;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 185;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 184; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 189;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 188.WSGR Docket No. 67237-702.60136. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 193;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 192;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 191; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 196;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 195.

37. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 200;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 199;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 198; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 203;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 202.

38. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 207;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 206;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 205; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 210;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 209.WSGR Docket No. 67237-702.60139. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 214;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 213;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 212; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 217;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 216.

40. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 221;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 220;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 219; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 224;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 223.

41. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 228;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 227;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 226; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 231;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 230.WSGR Docket No. 67237-702.60142. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 235;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 234;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 233; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 238;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 237.

43. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 242;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 241;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 240; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 245;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 244.

44. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 249;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 248;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 247; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 252;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 251.WSGR Docket No. 67237-702.60145. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 256;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 255;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 254; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 259;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 258.

46. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 263;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 262;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 261; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 266;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 265.

47. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 270;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 269;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 268; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 273;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 272.WSGR Docket No. 67237-702.60148. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 277;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 276;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 275; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 280;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 279.

49. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 284;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 283;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 282; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 287;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 286.

50. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 291;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 290;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 289; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 294;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 293.WSGR Docket No. 67237-702.60151. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 298;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 297;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 296; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 301;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 300.

52. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 305;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 304;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 303; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 308;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 307.

53. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 312;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 311;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 310; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 315;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 314.WSGR Docket No. 67237-702.60154. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 319;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 318;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 317; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 322;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 321.

55. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 326;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 325;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 324; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 329;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 328.

56. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 333;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 332;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 331; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 336;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 335.WSGR Docket No. 67237-702.60157. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 340;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 339;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 338; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 343;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 342.

58. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 347;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 346;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 345; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 350;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 349.

59. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 354;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 353;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 352; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 357;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 356.WSGR Docket No. 67237-702.60160. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 361;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 360;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 359; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 364;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 363.

61. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 368;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 367;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 366; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 371;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 370.

62. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 375;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 374;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 373; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 378;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 377.WSGR Docket No. 67237-702.60163. A composition comprising an antibody or a binding fragment thereof which specifically binds to the polymeric immunoglobulin receptor (plgR), wherein the antibody or the binding fragment thereof comprises(a) a heavy chain comprising:(i) a HCDR3 comprising a sequence set forth in SEQ ID NO: 382;(ii) a HCDR2 comprising a sequence set forth in SEQ ID NO: 381;(iii) a HCDR1 comprising a sequence set forth in SEQ ID NO: 380; and (b) a light chain comprising:(i) a LCDR3 comprising a sequence set forth in SEQ ID NO: 385;(ii) a LCDR2 comprising a sequence of WAS; and(iii) a LCDR1 comprising a sequence set forth in SEQ ID NO: 384.

64. The composition of any one of claims 1-63, wherein the antibody or the binding fragment thereof binds to plgR with an affinity of at least InM, at least O.lnM, at least O.OlnM, at least IpM, at least lOOnM, or at least 50nM.

65. The composition of any one of claims 1-64, wherein the composition is capable of inducing transcytosis via the activity of plgR.

66. The composition of any one of claims 1-65, wherein, when contacted to plgR, the antibody or the binding fragment thereof exhibits an increase of at least 1%, at least 5%, at least 10%, at least 20%, or at least 30% in transcytosis compared to an antibody that is not specific for plgR.

67. The composition of any one of claims 1-66, wherein the antibody or the binding fragment thereof, when contacted to an endothelial barrier expressing plgR, exhibits an increase of at least 1%, at least 5%, at least 10%, at least 20%, or at least 30% in transcytosis into the lumen compared to an antibody that is not specific for plgR.

68. The composition of any one of claims 1-67, wherein the antibody or the binding fragment thereof, when contacted to an epithelial barrier expressing plgR, exhibits an increase of at least 1%, at least 5%, at least 10%, at least 20%, or at least 30% in transcytosis into the lumen compared to an antibody that is not specific for plgR.

69. The composition of any one of claims 1-68, wherein the antibody or the binding fragment thereof is an scFv.

70. The composition of any one of claims 1-68, wherein the antibody or the binding fragment thereof is a sdAb, a Fab, or a VHH.

71. The composition of any one of claims 1-70, wherein the antibody or the binding fragment thereof is an IgG molecule.WSGR Docket No. 67237-702.60172. The composition of claim 71, wherein the IgG molecule is IgGl, IgG2, IgG3, or IgG4.

73. The composition of claim 72, wherein the IgG2 molecule is IgG2a, IgG2b, or IgG2c.

74. The composition of claim 72 or 73, wherein the IgG molecule is a mouse IgG (mlgG) or human IgG molecule (hlgG).

75. The composition of any one of claims 71-74, wherein the IgG molecule is an IgGl molecule.

76. The composition of claim 75, wherein the IgGl molecule is a human IgGl (hlgGl) molecule.

77. The composition of claim 76, wherein the hlgGl comprises one or more mutations.

78. The composition of claim 77, wherein the one or more mutations are selected from the group consisting of L234A, L235A, P329G in the hlgGl heavy chain, and any combination thereof.

79. The composition of claim 77 or 78, wherein the one or more mutations result in a reduction in Fc activity of the IgG molecule compared to an otherwise identical IgG molecule which does not comprise the one or more mutations.

80. The composition of any one of claims 1-68 and 71-79, wherein the antibody or binding fragment thereof comprises a constant region having an amino acid sequence with at least 80% sequence identity to a sequence set forth in SEQ ID NO: 80 or 81.

81. A nucleic acid encoding the antibody or the binding fragment thereof of any one of claims 1-80.

82. A vector comprising the nucleic acid of claim 81.

83. A cell comprising(a) the antibody or the binding fragment thereof of any one of claims 1-80; (b) the nucleic acid of claim 81; or(c) the vector of claim 82.

84. A composition comprising(a) the antibody or the binding fragment thereof of any one of claims 1-80; (b) the nucleic acid of claim 81;(c) the vector of claim 82; or(d) the cell of claim 83.

85. A pharmaceutical composition comprising (a) the antibody or the binding fragment thereof of any one of claims 1-80, the nucleic acid of claim 81, the vector of claim 82,WSGR Docket No. 67237-702.601the cell of claim 83, or the composition of claim 84 and (b) a pharmaceutically acceptable excipient.

86. A method of treating a plgR-expressing cancer in a subject in need thereof, the method comprising administering the antibody or the binding fragment thereof of any one of claims 1-80, the nucleic acid of claim 81, the vector of claim 82, the cell of claim 83, the composition of claim 84, or the pharmaceutical composition of claim 85.

87. A method of treating a metastasis or a local invasion of a plgR-expressing cancer in a subject in need thereof, the method comprising administering the antibody or the binding fragment thereof of any one of claims 1-80, the nucleic acid of claim 81, the vector of claim 82, the cell of claim 83, the composition of claim 84, or the pharmaceutical composition of claim 85.

88. The method of claim 86 or 87, wherein the plgR-expressing cancer is selected from the group consisting of a colorectal cancer, a pancreatic cancer, a gastric cancer, an esophageal cancer, a kidney cancer, an endometrial cancer, a cervical cancer, a breast cancer, a prostate cancer, a urinary bladder cancer, a cancer of the head and neck, a liver cancer, a gallbladder cancer, an ovarian cancer, and a non-small cell lung cancer.